

Date: 17th November, 2025

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Media Release for the half year ended on 30th September, 2025

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the media release of our Company for the half year ended on 30th September, 2025, the content of which is self-explanatory.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary and Compliance Officer

Encl.: As above

Media Release

Company Delivers Robust Performance in H1 FY26: Revenue up 136% YoY and EBITDA up 63% with Expanded Margins

Growth led by IPO-funded capacity expansion, value-added CDMO and private-label formulations, and wider customer and geographic reach

Ahmedabad, 17 November, 2025: Accretion Pharmaceuticals Limited (NSE Emerge: ACCPL), a leading manufacturer of high-quality pharmaceutical formulations and contract development and manufacturing organization (CDMO) services, announced its unaudited financial results for the half year ended 30th September, 2025.

Key Financial Highlights (Rs. In Crore):

Particulars	H1 FY26	H1 FY25	YoY %	H2 FY25	FY25	FY24	YoY %
Net Revenue	43.74	18.56	135.59%	38.81	57.38	33.67	70.43%
*EBIDTA (Excluding Other Income)	7.07	4.34	62.94%	7.54	11.88	7.49	58.64%
EBIDTA Margin %	16.17%	23.38%	(721 bps)	19.43%	20.71%	22.25%	(154 bps)
PAT	4.75	2.46	92.81%	4.33	6.79	3.88	75.31%
PAT Margin %	10.87%	13.28%	(241 bps)	11.15%	11.84%	11.51%	33 bps

*Excluding Other Income

Financial Results Highlights for the Half year ended 30th September 2025:

- **Net revenue in H1 FY26 stood at Rs.43.74 crore**, up 135.59% YoY, driven by strong volume expansion post IPO-funded capex, a richer mix of value-added CDMO and private-label formulations across oral solids, liquids, external preparations and powders combined with new customer additions and an expanded customer and geographic base.
- **EBITDA increased 62.94% YoY to Rs. 7.07 crore**, with an EBITDA margin of 16.17% in H1 FY26. This growth was led by robust revenue traction, better utilisation of newly added capacities and an improved mix of higher-margin, value-added products. The Company is further focused on margin enhancement through strategic bulk sourcing, supplier diversification, efficiency gains from new machinery, sharper batch planning and tighter working-capital discipline.
- **Profit after Tax rose 92.81% YoY to Rs. 4.75 crore in H1 FY26, with a PAT margin of 10.87%**. The increase was driven by higher operating profits and reduced finance costs following loan repayments from IPO proceeds, even after absorbing a higher tax outgo.
- Basic EPS for H1 FY26 stood at Rs. 4.61, reflecting strong earnings from these growth investments.

Management Comment:

Commenting on the Company's performance, **Mr. Vivek Ashok Kumar Patel, Promoter, Managing Director, Accretion Pharmaceuticals Limited** said:

"H1 FY26 has been a period of strong and disciplined growth. We delivered revenue of ₹43.74 crore, up 135.59% YoY, EBITDA of ₹7.07 crore, up 62.94% YoY, and PAT of ₹ 4.75 crore, up 92.81% YoY. This robust performance reflects the strength of our integrated CDMO and private-label formulation model across oral solids, liquids, external preparations, and powders.

Our IPO-funded capital investments in new equipment and facility upgrades at the Ahmedabad site have significantly increased our capacity, improved productivity, and enhanced our ability to handle a more complex and value-added product mix.

We continue to scale sustainably, backed by a diversified domestic and export customer base and end-to-end development, dossier, and supply capabilities. We also strengthened our global market roadmap with cGMP approval from PMRA, Malawi, enabling direct exports into key African markets.

With WHO-cGMP, GLP, ISO 9001/14001/22000 certifications, and multiple country approvals including Cambodia, Rwanda, Nigeria and Malawi, along with strong installed capacities and in-house QC infrastructure, Accretion Pharma is well positioned to deliver reliable, compliant growth in the coming quarters. We remain disciplined and optimistic about the road ahead.

Thank you for your ongoing support and trust in Accretion Pharmaceuticals Limited."

Company Overview

Accretion Pharmaceuticals Limited, established in 2012 and headquartered in Ahmedabad, Gujarat, India, is a fast-growing pharmaceutical company listed on the NSE Emerge platform (since May 21, 2025). Specializing in the development, manufacturing, and marketing of high-quality generic and branded formulations, the Company offers a diverse portfolio including tablets, capsules, oral liquids, oral powder and external preparation. Operating from a state-of-the-art facility at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213. Accretion provides contract development and manufacturing organization (CDMO) services, private labeling, and third-party manufacturing for merchant exporter, domestic marketer and international clients.

Our Company is WHO- cGMP, GLP, Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP, ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certified and is led by an experienced board of directors, and a professional and experienced management team with extensive experience in the pharmaceutical.

For more details please visit: www.accretionpharma.com

For further information please contact:

Company: Roshni Shah Company Secretary & Compliance Officer Accretion Pharmaceuticals Limited E-mail: compliance@accretionpharma.com	Investor Relations: Savli Mangle / Rupesh Rege Adfactors PR Pvt. Ltd. Email: savli.Mangle@adfactorspr.com rupesh.rege@adfactorspr.com
--	--

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.